Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...
Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...
About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...
This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...
Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...
Credit: Bristol Myers Squibb. The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, which included adults with relapsed or refractory CLL or SLL after progression on a BTKi and ...
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...
Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...
The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers ...
As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback